These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 16275818)
1. The trials and tribulations of pediatric drug trials. Shinnar S; Pellock JM Neurology; 2005 Nov; 65(9):1348-9. PubMed ID: 16275818 [No Abstract] [Full Text] [Related]
2. Severe carbamazepine toxicity induced by concurrent erythromycin therapy. Mota CR; Carvalho C; Mota C; Ferreira P; Vilarinho A; Pereira E Eur J Pediatr; 1996 Apr; 155(4):345. PubMed ID: 8777933 [No Abstract] [Full Text] [Related]
5. DRESS: is oxcarbazepine safer than carbamazepine? An analysis of the French Pharmacovigilance database. Le Louët H; Thomas L; Babai S Eur J Neurol; 2008 May; 15(5):e43. PubMed ID: 18355308 [No Abstract] [Full Text] [Related]
6. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Kruszewski SP; Klotz SG Neurology; 2007 Feb; 68(6):472; author reply 472-3. PubMed ID: 17283329 [No Abstract] [Full Text] [Related]
7. Three new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide. Leppik IE J Child Neurol; 2002 Jan; 17 Suppl 1():S53-7. PubMed ID: 11918464 [TBL] [Abstract][Full Text] [Related]
13. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Kim WJ; Lee JH; Yi J; Cho YJ; Heo K; Lee SH; Kim SW; Kim MK; Kim KH; In Lee B; Lee MG Pharmacogenet Genomics; 2010 Apr; 20(4):249-56. PubMed ID: 20216337 [TBL] [Abstract][Full Text] [Related]
14. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Mogensen PH; Jórgensen L; Boas J; Dam M; Vesterager A; Flesch G; Jensen PK Acta Neurol Scand; 1992 Jan; 85(1):14-7. PubMed ID: 1546529 [TBL] [Abstract][Full Text] [Related]
15. Two new drugs for epilepsy. Med Lett Drugs Ther; 2000 Apr; 42(1076):33-5. PubMed ID: 10803174 [No Abstract] [Full Text] [Related]
16. Challenges in international pediatric pharmacology: a milestone meeting in Shanghai. MacLeod S; Peterson R; Wang Y; Li Z; Gui Y; Schaller J Paediatr Drugs; 2007; 9(4):215-8. PubMed ID: 17705560 [No Abstract] [Full Text] [Related]
17. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Miller AD; Krauss GL; Hamzeh FM Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458 [TBL] [Abstract][Full Text] [Related]
18. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Deckers CL; Hekster YA; Keyser A; Meinardi H; Renier WO Neurology; 2000 Jul; 55(1):154-5. PubMed ID: 10891937 [No Abstract] [Full Text] [Related]
19. Active control trials for epilepsy: avoiding bias in head-to-head trials. French JA; Kryscio RJ Neurology; 2006 May; 66(9):1294-5. PubMed ID: 16682655 [No Abstract] [Full Text] [Related]
20. [Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome]. Kholodov LE; Prityko AG; Ivanova ES; Sokolov AV; Tishchenkova IF; Dubrovina LIu; Postnikov SS; Tatarinov PA; Kopanev IuA; Veselov NK Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(3):35-40. PubMed ID: 7571921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]